Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,592

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,831

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J. H., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 731

Whipple's Disease

Fenollar, F., Puéchal, X., & Raoult, D. (2007) · New England Journal of Medicine · doi:10.1056/nejmra062477 · Cited by 651

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. H., & Ranst, M. A. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 644

New insights into the antiviral effects of chloroquine

Savarino, A., Trani, L. D., Donatelli, I., Cauda, R., & Cassone, A. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70361-9 · Cited by 570

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

Al‐Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 477

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Colson, P., Rolain, J., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 471

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

Rolain, J., Colson, P., & Raoult, D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.05.015 · Cited by 408

B5N10 Nanocarrier Functionalized with Al, C, Si Atoms: A Drug Delivery Method for Infectious Disease Remedy

Mollaamin, F., & Monajjemi, M. (2024) · OBM Genetics · doi:10.21926/obm.genet.2401214 · Cited by 4

Investigating the Antiproliferative Activity of Novel 4‐Chloro‐8‐Nitro‐1,2‐Dihydro‐3‐Quinoline Acylhydrazones on Human Cervical Cancer Cell Lines

Nandakumar, V., Ramasamy, S. S., Adhigaman, K., Arumugam, D., Shankar, R., Vivek, R., Athimoolam, S., & Thangaraj, S. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401636 · Cited by 3

Drug delivery using doping of boron nitride nanosensor towards releasing chloroquine drug in the cells: A promising method for overcoming viral disease

Mollaamin, F., & Monajjemi, M. (2024) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v53n2.114450 · Cited by 4

Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection

Mutmainah, M., Murai, Y., Fujimoto, A., Kawamura, R., Kitamura, A., Koolath, S., Usuki, S., Sasaki, M., Orba, Y., Igarashi, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83633-8 · Cited by 3

COVID-19: The Case of Three Patients with the Same Diagnosis but Different Clinical and Laboratory Features

Atere, M., Singh, S., Arora, K., Khan, Z., Muzangwa, L., Bhavsar, U., & Nfonoyim, J. M. (2020) · Case Reports in Medicine · doi:10.1155/2020/9185041 · Cited by 3

Evaluation of the epidemiological pattern of COVID-19 applying basic reproduction number: An educational review article

Mirmohammadkhani, M., Paknazar, F., & Rashidy‐Pour, A. (2020) · کومش · doi:10.29252/koomesh.22.3.373 · Cited by 3

Recommendations for the follow-up of patients with cardiovascular disease when administering potentially effective medications for the treatment of COVID-19 with a purpose to reduce the risk of QT prolongation and sudden cardiac death

Garvanski, I., Petrov, I. S., & Simova, I. I. (2020) · Bulgarian Cardiology · doi:10.3897/bgcardio.26.e52960 · Cited by 3

Consideraciones actuales de antimaláricos en la infección por SARS-COV-2 y su impacto

Abuabara-Franco, E., Bohórquez-Rivero, J., Restom-Arrieta, J., Sáenz-López, J., Correa-Guerrero, J., & Mendoza-Paternina, C. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.supl.2.406 · Cited by 3

Hidroxicloroquina para manejo de infección por SARS-CoV-2

Bernal, E. A., Zea, A. L., Salazar-Rey, M., Gomez-Laiton, E., & Camacho-López, P. A. (2020) · Acta Médica Colombiana · doi:10.36104/amc.2020.1880 · Cited by 3

Novel immunogenomic insights of corona virus disease (COVID-19): Available potential immunotherapeutics, current challenges, immune cell recognition and ongoing managerial strategies

Haneef, K., Asghar, M. U., & Ali, A. (2020) · Biomedical Research and Therapy · doi:10.15419/bmrat.v7i8.620 · Cited by 3

Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations

Biswas, P. S., & Sen, D. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620957141 · Cited by 3

In Silico Study of Pacific oyster Antiviral Polypeptides as Potential Inhibitory Compounds for SARS-CoV-2 Main Protease

Mohammadi, M., Rajabi, S., Piroozmand, A., & Mirhosseini, S. A. (2020) · Jentashapir Journal of Cellular and Molecular Biology · doi:10.5812/jjcmb.108932 · Cited by 3

The Role of Nanoparticles as Nanocarriers for the Controlled Release of some Potential Existing Antiviral Drugs for SARS-CoV-2 Management: A Review

Ejeromedoghene, O., Orege, J. I., Onwuka, J. U., Adebule, A. P., Ehianeta, T. S., Okonkwo, B. O., & Akinyeye, R. O. (2020) · Coronaviruses · doi:10.2174/2666796701999201209142419 · Cited by 3

Differential Diagnosis and Possible Therapeutics for Coronavirus Disease 2019

Chintagunta, A. D., Kumar, M., Kumar, N. S. S., & Kumar, S. (2020) · Medical virology · doi:10.1007/978-981-15-6006-4_4 · Cited by 3

COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri

KILIÇ, C., AYDIN, S., & Kılıç, F. S. (2021) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.834991 · Cited by 3

In Silico Screening of Some Anti-Cancer Drugs Against the Main Protease of COVID-19 Using Molecular Docking

Ramazani, A., & Ouni, L. (2022) · Letters in Organic Chemistry · doi:10.2174/1570178619666220622091801 · Cited by 3

Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options

Alrahmany, D., & Ghazi, I. M. (2020) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000242 · Cited by 3

The rationale for current pharmacotherapy of COVID-19

Yunusoğlu, O., & Ali, H. S. (2020) · Eastern Journal Of Medicine · doi:10.5505/ejm.2020.29053 · Cited by 3

Recommendations for the management of COVID 19 patients regarding proarrhythmic effects of some current treatments, specifically if these patients suffer from arrhythmias, and for those receiving antiarrhythmic therapy.

Av, A., Oseroff, O., Sansalone, R., Zhelyakov, E. G., Cappato, R., Snezhitskiy, V. А., Канорский, С. Г., Abzalieva, S. A. S., Belenkov, Y. N., Karpenko, Y., et al. (2020) · Kardiologiia · doi:10.18087/cardio.2020.10.n1283 · Cited by 3

Potential Antiviral Effect of Chloroquine Therapy against SARS-CoV-2 Infection

Musa, I. R. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.4854 · Cited by 2

Lines of Treatment of COVID-19 Infection

ElGoly, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90595-4.00002-9 · Cited by 3

Potential interactions between antineoplastic agents and medicines used to treat Covid-19

da Silva, M. J. S., Osorio-de-Castro, C. G. S., Paes, R. D., Negrete, C. L., Eugênio, E., Moraes, E. L., & Livinalli, A. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211040494 · Cited by 5

Coronavirus Disease (COVID-19), Chemical Structure, Therapeutics, Drugs and Vaccines

ATiROĞLU, V., Atiroğlu, V., Atiroğlu, A., Özsoy, M., Özacar, M., & Özacar, M. (2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac121.547566 · Cited by 3

Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World

Doshi, G., Ved, H. S., & Thakkar, A. P. (2020) · Coronaviruses · doi:10.2174/2666796701999200623172631 · Cited by 3

Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19Preprint

Mina, F. B., Rahman, M. A., Das, S., Karmakar, S., & Billah, M. (2020) · doi:10.22541/au.158739631.11698779 · Cited by 3

Care of Immunocompromised Patients with Head and Neck Cancer During the COVID-19 Pandemic: Two Challenging and Informative Clinical CasesPreprint

Civantos, A. M. (2020) · doi:10.22541/au.158636352.27616577 · Cited by 3

COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment

Vounotrypidis, P. (2020) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.31.3.275 · Cited by 3

A Mechanism of Action for Hydroxychloroquine and Azithromycin to Inhibit Coronavirus Disease COVID-19Preprint

Schaper, C. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12148914 · Cited by 3

Visualization analysis of the characteristics of COVID-19 clinical trialsPreprint

Cai, X., Zheng, Z., Huang, J., & Su, Q. (2020) · doi:10.21203/rs.3.rs-21472/v2 · Cited by 3

COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question

Triggle, C. R., & MacDonald, R. S. (2025) · Viruses · doi:10.3390/v17070881 · Cited by 2

From Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID‐19 Pandemic—A Systematic Review and Meta‐Analysis

do Nascimento, B. B., Belline, B. G., de Souza, L. A., Andrade, J. C. B. N., & Fiol, F. D. S. D. (2026) · International Journal of Microbiology · doi:10.1155/ijm/8643896 · Cited by 2

CORONAVIRUS AND ITS MAIN PROTEASE: AN INSIGHT FOR DRUGS DESIGN BY MOLECULAR DOCKING

Gonçalves, S. Q. B., Filho, E. A. D. S., de Oliveira, O. V., & Gonçalves, A. D. S. (2020) · Revista Ifes Ciência · doi:10.36524/ric.v6i1.749 · Cited by 2

The Antioxidant Arsenal Against COVID-19

Mudgal, G., Kaur, J., Chand, K., & Singh, G. B. (2021) · Molecular and integrative toxicology · doi:10.1007/978-3-030-83446-3_16 · Cited by 2

Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic

Mir, I., Aamir, S., Shah, S. R. H., Shahid, M., Amin, I., Afzal, S., Nawaz, A., Khan, M. U., & Idrees, M. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0024 · Cited by 2

Computational Method on Hydroxychloroquine and Azithromycin for SARS-CoV-2: Binding Affinity Studies

Vaishnav, Y., Banjare, L., Verma, S., Sharma, G., Biswas, D., Tripathi, A. K., SHAIK, A. B., Bhandare, R. R., Kaur, A., & Manjunath, K. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00922 · Cited by 2

Knowledge and practice in Jordan regarding the outbreak and prevention of COVID-19: a questionnaire-based study

Al-Shawabkeh, J. D., Laban, N. A., Husein, N., & Jaber, D. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i4.18 · Cited by 2

“Pandemics-on-a-Chip”: Organ-on-a-Chip Models for Studying Viral Infections

Lima, A. M., Feitor, J. F., Ferreira, V. G., Almeida, M. B., Brazaca, L. C., Cardoso, D. R., & Carrilho, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-27922-5_8 · Cited by 2

Molecular docking of some Triphenyltin (IV) aminobenzoate compounds as potential antiviral agents

Hadi, S., Noviany, N., & Wahyudi, S. T. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00661 · Cited by 2

Repositioning antivirals against COVID-19: Synthetic pathways, mechanisms, and therapeutic insights

Bhat, A. A., Singh, I., Farid, A., Wani, A. W., Khanday, F. A., Wani, A. K., Shah, N., Hassan, A., Kabrah, A. M., Qusty, N. F., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107724 · Cited by 2

Synthesis and anti-SARS-CoV-2 potential of novel coumarin hybrids: a combined wet/dry lab approach targeting M Pro , Nsp15 and spike protein

Kausar, R., Mansha, A., Zahoor, A. F., & Haroon, M. (2025) · RSC Advances · doi:10.1039/d5ra02615f · Cited by 2

Reporte de 4 casos COVID-19 hospitalizados en unidad de cuidados intensivos en una institución hospitalaria en Barranquilla, Colombia

Pertuz, S. P. I., Aroca, G., Velez-Verbel, M. D., Osorio, A. G. C., Cadena-Bonfanti, A., Correa-Monterrosa, M., Castro, J. L., Brochado, L., Armesto, W., Vasquez, T. C., et al. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.supl.2.420 · Cited by 2

COVID-19’un Tanı ve Tedavi Sürecinde Hematolojik Parametreler

Orhan, M. F., & Büyükavcı, M. (2020) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.718051 · Cited by 2

Covid-19 enfeksiyonu olan hastalarda göz bulguları ve bulaş riski

ELİBOL, E. S., & Elbay, A. (2020) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.727154 · Cited by 2

Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy

Sen, S., Werner, A. M., & Shekhar, A. C. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00741-x · Cited by 2

Drug Safety Issues in Therapy COVID-19

Levitova, D. G., Gracheva, S. A., Samoylov, A. S., Udalov, U. D., Praskurnichiy, E. A., & Parinov, O. V. (2020) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2020-10-3-165-187 · Cited by 2

The Novel Corona Virus COVID-19 and Spinal Surgery Practice: Review and Updates

Elkazaz, M., Abou-Madawi, A., Khattab, M. F., Elshatoury, H., & Elkhatib, E. (2020) · Egyptian Spine Journal · doi:10.21608/esj.2020.31620.1137 · Cited by 2

Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19)

Mbaye, M. M., Khalfi, B. E., Hafiane, S. E., & Soukri, A. (2020) · Annual Research & Review in Biology · doi:10.9734/arrb/2020/v35i630237 · Cited by 2

Hydroxychloroquine, dermatology, and SARS‐CoV‐2: Updating an old association

Diotallevi, F., Campanati, A., Radi, G., Luchetti, M. M., Benfaremo, D., Tagliati, C., Simonetti, O., & Offidani, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26322 · Cited by 2

Treatment of Coronavirus Disease 2019: Shooting in the Dark

Tamargo, J. L. (2020) · European Cardiology Review · doi:10.15420/ecr.2020.21 · Cited by 2

Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician

Crivelari, N. C., de Oliveira, G. Q., Park, C. H. L., Riemma, G. D. C., Costa, I. B. S. D. S., Lacerda, M., de Oliveira, G. M. M., Darrieux, F., Sacilotto, L., & Hajjar, L. A. (2020) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200125 · Cited by 2

Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak

Tandon, N., Luxami, V., Tandon, R., & Paul, K. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201124141103 · Cited by 2

A Possible Destruction of SARS-CoV-2 by a Cylindrical Probe Coated with the Graphene Oxide: A Thermal-based Model

(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac115.1270612716 · Cited by 2

Review the Use of Antivirus for COVID-19 Treatment

Prayitno, L., Mawuntu, J. R., Herna, & Angkasawati, T. J. (2020) · Journal of Health Management · doi:10.1177/0972063420983113 · Cited by 2

Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients

Khudhair, Z. T., Shihab, M. S., & Hamah-Ameen, B. A. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021040130 · Cited by 2

Probing the Neuro-psychological Changes Observed with the Administration of COVID-19 Drugs

Chatterjee, I., & Bansal, V. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221223112247 · Cited by 2

Le carré de White et Green et la loi d’inverse opportunité : deux concepts en soins primaires au service de la prise en charge des patients atteints de la Covid-19

CADWALLADER, J.-S., Breton, J. L., Lorenzo, A., LEBEAU, J.-P., & POUCHAIN, D. (2020) · EXERCER · doi:10.56746/exercer.2020.164.261 · Cited by 2

Impact of covid-19 on economy: A critical review

Harsimran, S., Kumar, S., & Rakesh, K. (2020) · i-manager s Journal on Humanities & Social Sciences · doi:10.26634/jhss.1.3.17632 · Cited by 2

CORONAVIRUS DISEASE (COVID-19) TREATMENT ALGORITHMS IN PATIENTS WITH QT INTERVAL PROLONGATION

Kalatsei, L. V., Snezhitskiy, V. А., & Av, A. (2020) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2020-18-2-203-210 · Cited by 2

Symptoms, Transmission, Prevention and Treatment of Pandemic Corona Virus: A Review

Kebede, T., Kumar, D., & Sharma, P. K. (2020) · Coronaviruses · doi:10.2174/2666796701999200713191436 · Cited by 2

The COVID-19 era: the view from Nigeria

Oleribe, O. O., Oskouipour, P., Nwanyanwu, O., & Taylor-Robinson, S. D. (2020) · QJM · doi:10.1093/qjmed/hcaa297 · Cited by 2

¿Profilaxis con Cloroquina y/o Hidroxicloroquina para COVID-19?

Rojas, G. A. S., Bayona, D. A. E., & Bayona, C. A. E. (2020) · Investigatio · doi:10.31095/investigatio.2020.15.1 · Cited by 2

An Overview of COVID-19 Medicines in Current Guidelines

GÖKÇE, M., & Güler, E. M. (2020) · Bezmialem Science · doi:10.14235/bas.galenos.2020.4522 · Cited by 2

Aspectos clínicos e inmunológicos de la infección por SARS-CoV-2

Chaparro-Mérida, N. A., & Lacato, A. O. F. (2020) · Salud UIS · doi:10.18273/revsal.v52n3-2020010 · Cited by 3

Effectiveness and quality analysis of methods in studies for the treatment of COVID-19

Milagre, S. T., Pereira, A. A., Andrade, A. D. O., Palis, A. D. A., Cabral, A. M., Barreto, C. G. L., de Souza, D. B., Silva, F. D. P., Santos, F. P., Silva, G. L., et al. (2021) · Research on Biomedical Engineering · doi:10.1007/s42600-021-00134-7 · Cited by 2

A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2

Ikonne, E. U., Ikpeazu, V. O., Ugbogu, O. C., Emmanuel, O., Nwakuche, I. P., Iweala, E., & Ugbogu, E. A. (2021) · Drug metabolism and drug interactions · doi:10.1515/dmpt-2020-0184 · Cited by 2

Single-Cell Gene Regulatory Network Analysis Reveals Potential Mechanisms of Action of Antimalarials Against SARS-CoV-2

Cai, J. J., & Osorio, D. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-79290-9_8 · Cited by 2

COVID‐19 Pandemic: Management and Challenges

Saberi-Hasanabadi, P., & Mohammadi, H. (2021) · Pharmaceutical and Biomedical Research · doi:10.18502/pbr.v7i2.7359 · Cited by 2

COVID-19

Beltz, L. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98809-4.00013-9 · Cited by 2

A ciência como um processo: lições epistemológicas da pandemia

Guzzo, G. B., & Dall’Alba, G. (2021) · ACTIO Docência em Ciências · doi:10.3895/actio.v6n3.13133 · Cited by 2

Modulation of post-pacing action potential duration and contractile responses on ventricular arrhythmogenesis in chloroquine-induced long QT syndrome

Liu, C., Lin, F.-J., Chen, Y., Lin, Y., Lu, Y., Chan, C., Higa, S., Chen, S., & Chen, Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175493 · Cited by 2

Discovery, synthesis and in silico approach of pyrrolo [3,4- c ]pyrroles as SARS-CoV-2 m pro inhibitors

Mani, K. S., Sundarraj, R., & Prabha, B. S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2174599 · Cited by 2

The Penn Medicine COVID-19 Therapeutics Committee—Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency

Anesi, G. L., Degnan, K. O., Dutcher, L. S., Saw, S., Maguire, C., Binkley, A., Patel, S., Athans, V., Barton, T. D., Binkley, S., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad428 · Cited by 2

Molecular Docking to Discover Potential Bio-Extract Substitutes for Hydroxychloroquine against COVID-19 and Malaria

Snehasis, S. Z. N. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24323192940 · Cited by 2

Pharmacological management of COVID-19

Dhaliwal, M., & Raghunathan, V. (2020) · JOURNAL OF PEDIATRIC CRITICAL CARE · doi:10.4103/jpcc.jpcc_66_20 · Cited by 2

THE IMPACT OF NATURAL COMPOUNDS IN THE FIGHT AGAINST COVID-19: A REVIEW

Kiaka, J. P., Moundzounga, T. H. G., & Yasmine, A. Y. O. (2020) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.110545 · Cited by 2

Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent

Mansilla, E., Martínez, R. R., Marin, G. H., Filho, I. J. Z., Rivas, E., Rivas, J., de Carvalho, K. A. T., Dayer, M. R., & Samadikuchaksaraei, A. (2020) · Pharmacology & Pharmacy · doi:10.4236/pp.2020.116009 · Cited by 2

Can HCQ Be Considered a “Safe Weapon” for COVID-19 in the Indian Population?

Thangaraju, P., Venkatesan, N., Venkatesan, S., Gurunthalingam, M. P., & Thangaraju, E. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00392-z · Cited by 2

Perspectives on COVID-19 therapies: conflicts and consensus

Romeiro, K., Batista, R. C. D. S., Gominho, L. F., de Arruda, C. V. B., Moura, A. C., de Albuquerque, D. S., Gerbi, M. E. M. D. M., & Cassimiro, M. (2020) · Research Society and Development · doi:10.33448/rsd-v9i9.7019 · Cited by 1

Hydroxy-chloroquine to treat COVID-19 – infected patients: Some lessons from medical anthropology and history of medicine

Charlier, P., Donell, S. T., Lippi, D., Nerlich, A. P., Asensi, V., Perciaccante, A., Appenzeller, O., & Bianucci, R. (2020) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2020.100587 · Cited by 2

How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.

Eslami, P., Tabary, M., Moghadam, A. D., & Khaheshi, I. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i3.9848 · Cited by 2

Novel Corona-Virus Disease 2019 (COVID-19): A Perilous Life- Threatening Epidemic

Goel, S., & Dayal, R. (2020) · Coronaviruses · doi:10.2174/2666796701999200921094439 · Cited by 2

Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?

Shankar, P. R., Palaian, S., & Gulam, S. M. (2020) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_404_20 · Cited by 2

Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19

Shirbhate, E., Patel, P., Patel, V. K., Veerasamy, R., Sharma, P. C., Sinha, B. N., & Rajak, H. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201204162103 · Cited by 2

2020, um problema de saúde em escala global: uma historiografia sobre a pandemia de CoViD-19 e aspectos relacionados à prática de atividade física

Martins, L., & Soeiro, R. (2020) · Revista de Educação Física / Journal of Physical Education · doi:10.37310/ref.v89i3.2703 · Cited by 2

Characteristic Features of Coronavirus Disease-2019 (COVID-19) Pandemic: Attention to the Management and Control in Egypt

El-Subbagh, N. H., Rabie, R., Mahfouz, A. A., Aboelsuod, K. M., El-Shabrawy, M., Abdelaleem, H. M., Elhammady, B. E., Abosaleh, W., Salama, L., Badreldeen, S., et al. (2021) · Journal of Disaster Research · doi:10.20965/jdr.2021.p0070 · Cited by 3

Computational Modeling of Chloroquine Analogues for Development of Drugs Against Novel Coronavirus (nCoV)

Kumar, V., & Roy, K. (2021) · Methods in pharmacology and toxicology · doi:10.1007/7653_2020_55 · Cited by 2

LONG-TERM IMMUNOLOGICAL CONSEQUENCES OF COVID-19 ON HEALTH

KADAM, H., KAPHARE, G., AVHAD, R., Aher, P. R., GADE, N., BAJAIT, M., Talele, S. G., & Jadhav, A. G. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022v14i1.42311 · Cited by 2

A Concise Review on Origin, Nature, Characteristic Features, and Plausible Drugs for Treatment against Covid-19

Mahadik, K. R. (2020) · Open Access Journal of Pharmaceutical Research · doi:10.23880/oajpr-16000220 · Cited by 2

A Comprehensive Review of the Cross-Disciplinary Impact of COVID-19 in IndiaPreprint

Dhawal, P. P., Kakodkar, S., Pawar, R., Bhome, S., & Barve, S. (2020) · Preprints.org · doi:10.20944/preprints202006.0131.v1 · Cited by 2

A Systematic Review on Coronavirus Disease 2019 (COVID-19)Preprint

Karim, H., & Khan, M. S. (2020) · Preprints.org · doi:10.20944/preprints202008.0516.v1 · Cited by 2

Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients – A Systematic ReviewPreprint

Freilich, D., Victory, J. M., & Gadomski, A. (2022) · medRxiv · doi:10.1101/2022.01.11.22269069 · Cited by 2

A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia.Preprint

Dongala, T., Ettaboina, S. K., & Katari, N. K. (2020) · doi:10.21203/rs.3.pex-880/v1 · Cited by 2

Information Disclosed in Patent Documents being the Source to Address Emergencies: A Strategy to Achieve Technological Developments Addressing COVID-19

Martins, T. D., & Cordeiro, D. S. (2021) · Recent Patents on Biotechnology · doi:10.2174/1872208315666210402112805 · Cited by 1

Caractéristiques épidémio-cliniques, biologiques et radiologiques des adultes atteints de COVID-19 au centre hospitalier de Kiffa, Assaba (Mauritanie).

Boushab, B. M., Fall-Malick, F. Z., Kelly, M., Baba, E.-V. O. A., Mohamed, O. O. S., Baba, S. O., & Al, E. (2021) · Revue Malienne d Infectiologie et de Microbiologie · doi:10.53597/remim.v16i1.1756 · Cited by 1

Much ado about nothing? Discrepancy between the available data on the antiviral effect of hydroxychloroquine in March 2020 and its inclusion in COVID-19 clinical trials and outpatient prescriptions

Vieux, N., Perrier, Q., Bedouch, P., & Épaulard, O. (2023) · Public Health · doi:10.1016/j.puhe.2023.09.018 · Cited by 1

Hydroxychloroquine in SARS-CoV-2 infection: Understanding the misadventure

Banji, D., & Banji, O. J. F. (2024) · Journal of Acute Disease · doi:10.4103/jad.jad_9_24 · Cited by 1

COVID-19 in Latin America: Clinical and immunological insights, vaccine development, and lessons for pandemic preparedness

Torres-Flores, A., Bautista-Sebastián, E., Rivera-Hernández, T., Ferat-Osorio, E. A., Arriaga‐Pizano, L., Cérbulo‐Vázquez, A., Ramírez-Ramírez, D., Bonifaz, L. C., Pelayo, R., & López-Macías, C. I. R. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102025 · Cited by 1

Potential Drugs for Treating COVID-19 Infection

Mohammadi, M., Sandle, T., Rajabi, S., Khorshidi, A., & Piroozmand, A. (2020) · International Journal of Infection · doi:10.5812/iji.106243 · Cited by 1

Atuação de enfermeiras(os) obstetras durante o trabalho de parto/parto: Relato de experiência

de Freitas, M. M. L., Magalhães, J. D. S., Menezes, C. P. D. S. R., de Sousa, L. M., Silva, C. D. S., #REF!, #., Lopes, A. G. F., & Araújo, M. M. D. S. (2020) · Editora Poisson eBooks · doi:10.36229/978-65-5866-037-8.cap.05 · Cited by 1

A Narration: 20th v/s 21st Century: Pandemic v/s Another Pandemic: Virus v/s Another Virus (Spanish Flu V/S COVID-19)

Saulat, A., & Jafri, A. N. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.1.594 · Cited by 1

Can we use hydroxychloroquine to treat COVID-19 now?

Chen, J., Liu, D., Yin, L., Zhang, L., & Lu, H. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106173 · Cited by 1

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Sahraei, Z., Shabani, M., Shokouhi, S., & Saffaei, A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105945 · Cited by 234

Chloroquine and hydroxychloroquine as potential therapies against COVID-19

Yewange, S., Deshpande, R. R., Waghmare, N., Vidyasagar, G., Bavage, S. B., & Bavage, N. B. (2020) · Cited by 1

Chloroquine as a prophylactic agent against COVID-19?

Gendrot, M., Javelle, É., Clerc, A., Savini, H., & Pradines, B. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105980 · Cited by 44

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Colson, P., Rolain, J., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 471